Sensitization of cervix cancer cells to Adriamycin by Pentoxifylline induces an increase in apoptosis and decrease
Alejandro Bravo-Cuellar1, Pablo C Ortiz-Lazareno, Jose M Lerma-Diaz
1División de Inmunología, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Sierra Mojada 800, Colonia Independencia, Guadalajara, Jalisco, CP 44340, México.
Molecular Cancer
|May 21, 2010
Summary
Pentoxifylline (PTX) enhances Adriamycin (ADR) chemotherapy by increasing apoptosis and reducing senescence in cervical cancer cells. This combination therapy shows promise for improving treatment outcomes against resistant cancer.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Chemotherapy resistance is a major challenge in cancer treatment.
- Adriamycin (ADR) induces apoptosis but cancer cells can develop resistance.
- Pentoxifylline (PTX), a methylxanthine drug, has shown potential antitumor properties.
Purpose of the Study:
- To investigate the effect of Pentoxifylline (PTX) pretreatment on Adriamycin (ADR)-induced apoptosis and senescence in cervical cancer cells.
- To evaluate the potential of PTX as an adjuvant therapy to overcome ADR resistance.
Main Methods:
- Cervical cancer cell lines (HeLa, SiHa) and HaCaT cells were treated with PTX, ADR, or PTX + ADR.
- Assays included WST-1 for toxicity, clonogenic assay for survival, flow cytometry for apoptosis and cell cycle, and microscopy for senescence.
- Gene and protein expression (caspase, IkappaBalpha, p53, HPV-E6/E7) were analyzed using RT-PCR and Western blot.
Main Results:
- PTX demonstrated toxicity and induced apoptosis in cervical cancer cells.
- The combination of PTX and ADR significantly reduced cancer cell survival and increased apoptosis compared to ADR alone.
- PTX inhibited ADR-induced senescence while enhancing apoptosis, suggesting a dual role in modulating cell fate.
- PTX increased IkappaBalpha levels and upregulated pro-apoptotic factors, sensitizing cells to ADR.
- PTX reduced HPV-E6/E7 expression in SiHa cells.
Conclusions:
- Pentoxifylline (PTX) effectively induces apoptosis but not senescence in cervical cancer cells.
- PTX enhances the efficacy of Adriamycin (ADR) by increasing apoptosis and reducing ADR-induced senescence.
- PTX holds potential as a sensitizing agent to improve chemotherapy outcomes in cervical cancer.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...